NCT02582190View on ClinicalTrials.gov

COlchicine for the Prevention of Post Electrical Cardioversion Recurrence of AF

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 2, 2017

Primary Completion Date

September 2, 2018

Study Completion Date

September 2, 2018

Conditions
Atrial Fibrillation
Interventions
DRUG

Colchicine group

antiarrhythmic therapy plus colchicine \& antiarrhythmic therapy alone.

Sponsors
All Listed Sponsors
lead

Elpen Pharmaceutical Co. Inc.

INDUSTRY